Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

T. Yoshino, D. Arnold, H. Taniguchi, G. Pentheroudakis, K. Yamazaki, R. H. Xu, T. W. Kim, Fuad Ismail, I. B. Tan, K. H. Yeh, A. Grothey, S. Zhang, J. B. Ahn, M. Y. Mastura, D. Chong, L. T. Chen, S. Kopetz, T. Eguchi-Nakajima, H. Ebi, A. Ohtsu & 6 others A. Cervantes, K. Muro, J. Tabernero, H. Minami, F. Ciardiello, J. Y. Douillard

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (Chinese Society of Clinical Oncology), Korea (Korean Association for Clinical Oncology), Malaysia (Malaysian Oncological Society), Singapore (Singapore Society of Oncology) and Taiwan (Taiwan Oncology Society). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

Original languageEnglish
Article numbermdx738
Pages (from-to)44-70
Number of pages27
JournalAnnals of Oncology
Volume29
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Medical Oncology
Colorectal Neoplasms
Guidelines
Singapore
Taiwan
Therapeutics
Malaysia
Expert Testimony
Politics
Korea
China
Japan

Keywords

  • Clinical practice guidelines
  • Colorectal cancer
  • Consensus
  • Pan-Asian

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer : A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. / Yoshino, T.; Arnold, D.; Taniguchi, H.; Pentheroudakis, G.; Yamazaki, K.; Xu, R. H.; Kim, T. W.; Ismail, Fuad; Tan, I. B.; Yeh, K. H.; Grothey, A.; Zhang, S.; Ahn, J. B.; Mastura, M. Y.; Chong, D.; Chen, L. T.; Kopetz, S.; Eguchi-Nakajima, T.; Ebi, H.; Ohtsu, A.; Cervantes, A.; Muro, K.; Tabernero, J.; Minami, H.; Ciardiello, F.; Douillard, J. Y.

In: Annals of Oncology, Vol. 29, No. 1, mdx738, 01.01.2018, p. 44-70.

Research output: Contribution to journalArticle

Yoshino, T, Arnold, D, Taniguchi, H, Pentheroudakis, G, Yamazaki, K, Xu, RH, Kim, TW, Ismail, F, Tan, IB, Yeh, KH, Grothey, A, Zhang, S, Ahn, JB, Mastura, MY, Chong, D, Chen, LT, Kopetz, S, Eguchi-Nakajima, T, Ebi, H, Ohtsu, A, Cervantes, A, Muro, K, Tabernero, J, Minami, H, Ciardiello, F & Douillard, JY 2018, 'Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS', Annals of Oncology, vol. 29, no. 1, mdx738, pp. 44-70. https://doi.org/10.1093/annonc/mdx738
Yoshino, T. ; Arnold, D. ; Taniguchi, H. ; Pentheroudakis, G. ; Yamazaki, K. ; Xu, R. H. ; Kim, T. W. ; Ismail, Fuad ; Tan, I. B. ; Yeh, K. H. ; Grothey, A. ; Zhang, S. ; Ahn, J. B. ; Mastura, M. Y. ; Chong, D. ; Chen, L. T. ; Kopetz, S. ; Eguchi-Nakajima, T. ; Ebi, H. ; Ohtsu, A. ; Cervantes, A. ; Muro, K. ; Tabernero, J. ; Minami, H. ; Ciardiello, F. ; Douillard, J. Y. / Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer : A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. In: Annals of Oncology. 2018 ; Vol. 29, No. 1. pp. 44-70.
@article{8d4dfa8753ca40e5ba599cb1f3992f4a,
title = "Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS",
abstract = "The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (Chinese Society of Clinical Oncology), Korea (Korean Association for Clinical Oncology), Malaysia (Malaysian Oncological Society), Singapore (Singapore Society of Oncology) and Taiwan (Taiwan Oncology Society). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.",
keywords = "Clinical practice guidelines, Colorectal cancer, Consensus, Pan-Asian",
author = "T. Yoshino and D. Arnold and H. Taniguchi and G. Pentheroudakis and K. Yamazaki and Xu, {R. H.} and Kim, {T. W.} and Fuad Ismail and Tan, {I. B.} and Yeh, {K. H.} and A. Grothey and S. Zhang and Ahn, {J. B.} and Mastura, {M. Y.} and D. Chong and Chen, {L. T.} and S. Kopetz and T. Eguchi-Nakajima and H. Ebi and A. Ohtsu and A. Cervantes and K. Muro and J. Tabernero and H. Minami and F. Ciardiello and Douillard, {J. Y.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/annonc/mdx738",
language = "English",
volume = "29",
pages = "44--70",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

T2 - A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

AU - Yoshino, T.

AU - Arnold, D.

AU - Taniguchi, H.

AU - Pentheroudakis, G.

AU - Yamazaki, K.

AU - Xu, R. H.

AU - Kim, T. W.

AU - Ismail, Fuad

AU - Tan, I. B.

AU - Yeh, K. H.

AU - Grothey, A.

AU - Zhang, S.

AU - Ahn, J. B.

AU - Mastura, M. Y.

AU - Chong, D.

AU - Chen, L. T.

AU - Kopetz, S.

AU - Eguchi-Nakajima, T.

AU - Ebi, H.

AU - Ohtsu, A.

AU - Cervantes, A.

AU - Muro, K.

AU - Tabernero, J.

AU - Minami, H.

AU - Ciardiello, F.

AU - Douillard, J. Y.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (Chinese Society of Clinical Oncology), Korea (Korean Association for Clinical Oncology), Malaysia (Malaysian Oncological Society), Singapore (Singapore Society of Oncology) and Taiwan (Taiwan Oncology Society). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

AB - The most recent version of the European Society for Medical Oncology (ESMO) consensus guidelines for the treatment of patients with metastatic colorectal cancer (mCRC) was published in 2016, identifying both a more strategic approach to the administration of the available systemic therapy choices, and a greater emphasis on the use of ablative techniques, including surgery. At the 2016 ESMO Asia Meeting, in December 2016, it was decided by both ESMO and the Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting, endorsed by both ESMO and JSMO, immediately after the JSMO 2017 Annual Meeting. The aim was to adapt the ESMO consensus guidelines to take into account the ethnic differences relating to the toxicity as well as other aspects of certain systemic treatments in patients of Asian ethnicity. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China (Chinese Society of Clinical Oncology), Korea (Korean Association for Clinical Oncology), Malaysia (Malaysian Oncological Society), Singapore (Singapore Society of Oncology) and Taiwan (Taiwan Oncology Society). The voting was based on scientific evidence and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.

KW - Clinical practice guidelines

KW - Colorectal cancer

KW - Consensus

KW - Pan-Asian

UR - http://www.scopus.com/inward/record.url?scp=85041205697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041205697&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx738

DO - 10.1093/annonc/mdx738

M3 - Article

VL - 29

SP - 44

EP - 70

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

M1 - mdx738

ER -